8. In regulation 13 (new regulation B17 and C17 (good manufacturing practice and good distribution practice))—U.K.
(a)in the inserted regulation B17—
(i)in paragraph (1)—
(aa)for “Ministers” substitute “ Secretary of State ”;
(bb)after “by regulations” insert “ in respect of Great Britain ”;
(ii)in paragraph (2)(b) after “UK marketing authorisation” insert “ or EU marketing authorisation ”;
(iii)in paragraph (3)—
(aa)after “have effect” insert “ in Great Britain ”;
(bb)for “exit day” in both places it occurs substitute “ IP completion day ”;
(iv)in paragraph (4)—
(aa)for “Ministers” substitute “ Secretary of State ”;
(bb)after “by regulations” insert “ in respect of Great Britain ”;
(b)in the inserted regulation C17—
(i)in paragraph (1), after “may publish” insert “ in relation to the manufacture or assembly of a medicinal product in, or import to, Great Britain ”;
(ii)in paragraph (3) for “exit day” in both places it occurs substitute “ IP completion day ”.
Commencement Information
I1Sch. 2 para. 8 in force at 31.12.2020 immediately before IP completion day, see reg. 1